CHEST 2021 Envisia Classifier
In this presentation, Dr Joseph Lasky discusses how the addition of the Envisia Genomic Classifier had a significant impact on physicians’ clinical decision making in the diagnosis and management of patients with ILD.
ATS 2021 Virtual ePoster Envisia Classifier Demonstrates Consistent Performance Across Gender, Age, and Smoking Status
The Envisia Genomic Classifier achieved 91% specificity and 63% sensitivity on 144 patients combining two prospective validation cohorts. This performance is retained across gender, age group and smoking status.
The addition of the Envisia Classifier and histopathology, especially those with a UIP pattern, significantly decreased the number of unclassifiable ILDs. The Envisia Classifier assists in making a diagnosis in patients with diverse underlying ILD diagnoses.